Under PureTech’s direction, in collaboration with leading T1D-focused organizations, T1D Innovations will create and fund companies to translate key medical discoveries into novel type 1 diabetes products
Sansum Diabetes Research Institute, University of California, Santa Barbara Conduct Innovative Artificial Pancreas – Ultra-Rapid-Acting Inhaled Insulin Trial Funded by JDRF
JDRF, Sansum Diabetes Research Institute, and the College of Engineering at University of California, Santa Barbara (UCSB) are pleased to announce the first successful clinical research trial using the artificial pancreas in conjunction with ultra-rapid-acting inhaled insulin.
JDRF Honors Researchers Whose Insights on Early Type 1 Diabetes Development Have Set the Stage for Disease Prevention in Children
The three winners of JDRF’s 2013 Mary Tyler Moore and S. Robert Levine, M.D., Excellence in Clinical Research Award have provided critical insights into the type 1 diabetes disease process in young children, laying the groundwork for targeted disease prevention strategies
JDRF, the leading global organization funding type 1 diabetes (T1D) research, today applauded the U.S. Food and Drug Administration (FDA) for its commitment to ensuring patients in the United States can access insulin pumps that can temporarily stop insulin delivery once sensor glucose levels ...
On Friday, September 20, Dave Prowten, President & CEO, JDRF Canada, and Charlotte Romain, Youth Ambassador, JDRF Canada joined Eleanor Fritz, Director, Compliance & Disclosure, Toronto Stock Exchange to open the market and raise awareness of the 25th annual ...
On behalf of the JDRF Canada Board of Directors, we are pleased to announce the appointment of Dave Prowten as the new President and Chief Executive Officer of JDRF Canada.
Sun Life Financial launches diabetes program to support preventative research across Canada
JDRF Announces Two Partnerships to Develop Stable, Pumpable Glucagon to Support Advanced Generation Artificial Pancreas Systems
JDRF announced today partnerships with both Xeris Pharmaceuticals, Inc., and LATITUDE Pharmaceuticals, Inc. (LPI), to support the development soluble glucagon formulations—an important step toward the advancement of future generation, fully automated and multi-hormonal ...
JDRF Extends Collaboration with BD to Develop Combined Infusion and Monitoring Products for People with Type 1 Diabetes
JDRF and BD (Becton, Dickinson and Company) (NYSE:BDX) are accelerating the development of new products that combine BD’s proprietary insulin infusion and glucose sensing technologies through a new collaboration announced today.
TORONTO (June 14, 2013) – On Sunday, June 16, 2013, the third annual Barrie Waterfront Half Marathon, 10K & 5K is taking place throughout the streets of Barrie and along scenic Lake Simcoe. New for 2013 is the partnership with JDRF, where runners and walkers can ...